E0671 + rabeprazole sodium

**E0671 + rabeprazole sodium** is a combination drug product containing rabeprazole sodium (a proton pump inhibitor) and E0671, a compound not comprehensively identified in publicly available drug databases. **Rabeprazole sodium** acts by inhibiting the gastric H+, K+-ATPase enzyme (the “proton pump”) in parietal cells of the stomach, blocking the final step of gastric acid production. This produces potent and long-lasting reduction of gastric acid secretion, making it effective in treating gastroesophageal reflux disease (GERD), peptic ulcer disease, Helicobacter pylori eradication regimens, and conditions such as Zollinger-Ellison syndrome[1][2][3]. The full properties, indications, and mechanisms of the E0671 component are unclear based on current sources; the description provided is therefore specific to rabeprazole sodium.